Trevi Therapeutics Inc. Financials

TRVI

All currency values in $ millions unless otherwise noted

Scroll

Showing 5 of 8 available years

Income Statement	DEC 2025 ~1.3:1 split	DEC 2024	DEC 2023 ~1.5:1 split	DEC 2022 ~2.8:1 split	DEC 2021
General & Administrative	$16	$12	$10	$10	$9
Research & Development	$33	$39	$24	$20	$23
Total Operating Expenses	$49	$52	$34	$30	$32
Operating Income	-$49	-$52	-$34	-$30	-$32
Non-Operating
Net Interest Expense	$7	$4	$4	-$1	-$1
Other Non-Operating Income (Expense)	-$0	-$0	$0	$2	-$0
EBT (Earnings Before Tax)	-$43	-$48	-$29	-$29	-$34
Income Tax Expense	-$0	-$0	-$0	-$0	-$0
Net Income
Net Income	-$43	-$48	-$29	-$29	-$34
EPS (Basic)	-$0.32	-$0.47	-$0.29	-$0.45	-$1.49
EPS (Diluted)	-$0.32	-$0.47	-$0.29	-$0.45	-$1.49
Weighted Avg Shares (Basic)	134.7M	102.0M	99.0M	64.5M	22.8M
Weighted Avg Shares (Diluted)	134.7M	102.0M	99.0M	64.5M	22.8M
Shares Outstanding	134.7M	102.0M	99.0M	64.5M	22.8M

Trevi Therapeutics (TRVI) financials: revenue, profit and margins

Trevi Therapeutics (TRVI) generated about n/a in revenue and -$51 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Trevi Therapeutics profitable?+

Trevi Therapeutics reported about -$51 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

More on TRVI: Overview · Quality scorecard · DCF valuation · Dividend safety

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 31 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 12 Oct 2026. How this is calculated.

Fiscal year ends Dec.

Peers

Pharmaceutical Preparations · Pick stocks to compare with TRVI

CompareIntrinsic value

CPHIChina Pharma Holdings Inc.

$0.59-3.28%15

BFRIBiofrontera Inc.

$0.90+1.55%30

TBPHTheravance Biopharma Inc.

No recent price82

MDGLMadrigal Pharmaceuticals, Inc.

$400.67+1.10%10

ATNMActinium Pharmaceuticals Inc.

$1.41+0.71%30

KPRXKiora Pharmaceuticals Inc.

$1.66-4.05%10

OGENOragenics Inc.

$0.37+0.00%20

ISCOInternational Stem Cell Corporation

$0.14+0.00%29

Held by ETFs

TRVI is in 31 US ETFs. The largest of them, with TRVI's weight in each:

Spot a number that looks wrong? Check it in TRVI's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing TRVI

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.